Article
Oncology
Xuan Zou, Xuan Lin, He Cheng, Yusheng Chen, Ruijie Wang, Mingjian Ma, Yu Liu, Zhengjie Dai, Yesboli Tasiheng, Yu Yan, Qinqin Hou, Fei Ding, Huan Chen, Xianjun Yu, Xu Wang, Chen Liu
Summary: This study systematically revealed the cellular properties and prognostic values of intratumoral TLSs in pancreatic ductal adenocarcinoma (PDAC) and described the potential impact of neoadjuvant treatment (NAT) on TLS development and function.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Byeong Geun Song, Wooil Kwon, Hyemin Kim, Eun Mi Lee, Young Min Han, Hongbeom Kim, Yoonhyeong Byun, Kyung Bun Lee, Kwang Hyuck Lee, Kyu Taek Lee, Jong Kyun Lee, Jin-Young Jang, Joo Kyung Park
Summary: CTCs can be reliably identified in early stages of PDACs, with CTC count potentially serving as a prognostic marker for resectable PDAC patients' survival.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Christine Nitschke, Benedikt Markmann, Marie Tolle, Jolanthe Kropidlowski, Yassine Belloum, Mara R. Goetz, Hartmut Schluter, Marcel Kwiatkowski, Marianne Sinn, Jakob Izbicki, Klaus Pantel, Cenap Gungor, Faik G. Uzunoglu, Harriet Wikman
Summary: This study used a microfluidic-based approach to detect circulating tumor cells (CTCs) in patients with pancreatic ductal adenocarcinoma (PDAC), and assessed the expression of retinoic acid receptor responder 1 (RARRES1) on CTCs for the first time. The results showed that the detection rate of CTCs was higher during follow-up, and high CTC counts during follow-up in resected patients were associated with early tumor relapse. Combining CTC detection and RARRES1 expression could predict a worse prognosis in patients after curative operation during follow-up.
Article
Oncology
Fabio Raineri, Sandrine Bourgoin-Voillard, Melissande Cossutta, Damien Habert, Matteo Ponzo, Claire Houppe, Benoit Vallee, Michele Boniotto, Mounira Chalabi-Dchar, Philippe Bouvet, Anne Couvelard, Jerome Cros, Anais Debesset, Jose L. Cohen, Jose Courty, Ilaria Cascone
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and resistant cancer with no effective therapy. Research shows that the pseudopeptide N6L targeting nucleolin can inhibit tumor growth and metastasis in PDAC by regulating the Wnt/beta-catenin pathway, suggesting it as a potential new therapeutic target.
Article
Biochemistry & Molecular Biology
Christine Nitschke, Benedikt Markmann, Leonie Konczalla, Jolanthe Kropidlowski, Thais Pereira-Veiga, Pasquale Scognamiglio, Martin Schonrock, Marianne Sinn, Marie Tolle, Jakob Izbicki, Klaus Pantel, Faik G. Uzunoglu, Harriet Wikman
Summary: This study found that the detection of CAMLs can provide prognostic information in PDAC patients, particularly when combined with CTCs. This indicates the potential of liquid biopsy marker analyses.
Article
Multidisciplinary Sciences
Deirdre Kruger, Nicola Lahoud, Yandiswa Y. Yako, John Dever, Martin Smith
Summary: This study aimed to evaluate the risk factors, symptoms, and potential prognostic biomarkers in PDAC, showing that platelet count, IL-15, and GM-CSF could be potential indicators of metastatic disease in PDAC patients. Some risk factors and symptoms did not differ across different stages of cancer.
Article
Immunology
Hao Yuan, Jinhui Liu, Li Zhao, Pengfei Wu, Guosheng Chen, Qun Chen, Peng Shen, Taoyue Yang, Shaoqing Fan, Bin Xiao, Kuirong Jiang
Summary: Through analysis of clinical information and genetic transcriptome data of PDAC patients, a m5C-related lncRNA prognostic risk model was established and its relationship with PDAC immune microenvironment was studied. The risk model showed predictive ability and could potentially serve as a therapeutic target for PDAC patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Dong Woo Shin, Jaewon Park, Jong-Chan Lee, Jaihwan Kim, Young Hoon Kim, Jin-Hyeok Hwang
Summary: This study investigated the predictive ability of intra-tumoral enhancement on computed tomography (CT) for the outcomes of patients with pancreatic ductal adenocarcinoma (PDA). The results showed that intra-tumoral contrast enhancement on CT is an independent prognostic factor in patients with non-metastatic PDA.
Article
Genetics & Heredity
Ioannis Vezakis, Antonios Vezakis, Sofia Gourtsoyianni, Vassilis Koutoulidis, Andreas A. Polydorou, George K. Matsopoulos, Dimitrios D. Koutsouris
Summary: In this study, we developed a fully automated pipeline for survival prediction in pancreatic ductal adenocarcinoma (PDAC) patients. By utilizing radiomics and machine learning techniques, we demonstrated the effectiveness and feasibility of this pipeline. The streamlined process improves efficiency and accuracy, laying the foundation for future research.
Article
Medicine, General & Internal
Abdessamad El Kaoutari, Nicolas A. Fraunhoffer, Luc Camoin, Yolande Berthois, Odile Gayet, Julie Roques, Martin Bigonnet, Claire Bongrain, Joseph Ciccolini, Juan L. Iovanna, Nelson J. Dusetti, Philippe Soubeyran
Summary: Through specific proteomic tools and bioinformatics analysis, we established the ubiquitin dependent proteome of 60 PDAC, identifying 38 ubiquitination site profiles correlated with tumor phenotype and having prognostic capabilities. These findings have potential application in predicting chemotherapy response and personalized treatment in clinical settings.
Review
Oncology
Ruben Bellotti, Cornelia Speth, Timon E. Adolph, Cornelia Lass-Florl, Maria Effenberger, Dietmar Oefner, Manuel Maglione
Summary: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related mortality, with recent research focusing on the microbial community in the pancreas as a potential target for early diagnosis and treatment. Specific microbial signatures may serve as novel screening tools, and micro- and mycobiota may represent promising targets for PDAC therapy.
Article
Oncology
Jana Kaethe Striefler, Hanno Riess, Philipp Lohneis, Sven Bischoff, Annika Kurreck, Dominik Paul Modest, Marcus Bahra, Helmut Oettle, Marianne Sinn, Henrik Blaeker, Carsten Denkert, Sebastian Stintzing, Bruno Valentin Sinn, Uwe Pelzer
Summary: High expression of MUC1 in PDAC patients is associated with decreased DFS and OS, suggesting it is a powerful prognostic marker for post-operative pancreatic ductal adenocarcinoma patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Yongfeng Xu, Qunli Xiong, Yang Yang, Ningna Weng, Junjun Li, Jinlu Liu, Xiaojuan Yang, Zhu Zeng, Zhiwei Zhang, Qing Zhu
Summary: The expression of NRDC is associated with clinical characteristics in pancreatic ductal adenocarcinoma, and it may serve as a circulating biomarker to evaluate the aggressive clinical features in patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Huanyu Wang, Weilin Mao, Wenhui Lou, Dayong Jin, Wenchuan Wu, Dansong Wang, Tiantao Kuang, Yefei Rong, Xuefeng Xu, Lei Zhang
Summary: The study revealed that PYCR1 expression was significantly higher in tumor tissues compared to normal tissues; Inhibiting PYCR1 expression could significantly inhibit proliferation and promote apoptosis of PDAC cells; PYCR1 may serve as a potential therapeutic and prognostic biomarker for pancreatic cancer treatment.
Article
Oncology
Tatsunori Miyata, Hiromitsu Hayashi, Yo-ichi Yamashita, Kazuki Matsumura, Yosuke Nakao, Rumi Itoyama, Takanobu Yamao, Masayo Tsukamoto, Hirohisa Okabe, Katsunori Imai, Akira Chikamoto, Takatoshi Ishiko, Hideo Baba
Summary: The pre-TI is an independent adverse prognostic factor predicting the relapse-free survival and overall survival of PDAC patients undergoing resection.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.
